Skip to main content
. Author manuscript; available in PMC: 2022 Aug 25.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2021 Jul 2;21(11):e886–e894. doi: 10.1016/j.clml.2021.06.021

Table 2.

Overview of TEAEs (Safety Analysis Set)

Copanlisib Plus R-B SRI (N = 10) Copanlisib Plus R-CHOP SRI (N = 11)
Any TEAE 10 (100) 11 (100)
 Grade ≥3 7 (70.0) 10 (90.9)
Any copanlisib-related TEAE 9 (90.0) 11 (100)
Any R-B- or R-CHOP-related TEAE 10 (100) 11 (100)
Any serious TEAE 2 (20.0) 8 (72.7)
 Grade ≥3 2 (20.0) 6 (54.5)
 Copanlisib-related 2 (20.0) 8 (72.7)

Data are presented as n (%).

Abbreviations: AE = adverse event; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SRI = safety run-in; TEAE = treatment-emergent adverse event.